It was almost a year ago that Immunomedics Inc. began two pivotal Phase III studies of epratuzumab to treat systemic lupus erythematosus. It said Wednesday it had licensed exclusive worldwide rights to develop, market and sell the product for all autoimmune disease indications to UCB SA. (BioWorld Today) Read More
